How is growth hormone assessed?

Because GH is secreted in pulses and fluctuates throughout the day, direct measurement is unreliable. Clinicians instead assess IGF-1, a more stable marker of overall GH activity. IGF-1 is measured as part of a broader hormonal and metabolic panel that may include testosterone, thyroid function, cortisol, and fasting glucose. If findings suggest clinical GH deficiency, your practitioner may recommend referral to an endocrinologist for stimulation testing.

Can lifestyle changes affect growth hormone levels?

Published evidence indicates that several modifiable factors influence GH secretion. Deep slow-wave sleep is the primary trigger for GH release, so improvements in sleep quality may positively affect output. Resistance training and high-intensity exercise can also stimulate GH secretion. Higher visceral adiposity is associated with reduced GH output, suggesting that fat loss may support improved secretion. A clinical assessment can identify modifiable factors alongside hormonal evaluation.

Hormonal Health in Men: Age-Related Changes

What Growth Hormone Does in the Male Body

Growth hormone (GH) is produced by the anterior pituitary gland and exerts effects across multiple physiological systems. In adults, its functions extend well beyond the linear growth it drives during childhood and adolescence.

Muscle, Fat, and Body Composition

Clinical data support the role of growth hormone in stimulating protein synthesis and promoting the mobilisation of stored fat for energy. GH contributes to lean muscle mass maintenance and influences how the body partitions energy between adipose tissue and skeletal muscle.

As GH declines, evidence suggests many men experience a shift toward increased visceral adiposity (deep abdominal fat) and reduced muscle density, even when training load and dietary intake remain stable. Body composition changes are multi-factorial; GH decline is one contributing variable among several, including changes in testosterone levels, insulin sensitivity, and physical activity patterns.

Published research in Frontiers in Aging has reviewed the clinical relationship between growth hormone decline and ageing, documenting effects on body composition, metabolic function, and musculoskeletal health.

Recovery, Sleep, and Metabolic Function

The majority of endogenous (internally produced) growth hormone secretion occurs during slow-wave (deep) sleep, which is why sleep architecture and GH output are closely interdependent. Poor sleep quality reduces GH secretion, reduced GH impairs tissue recovery, and impaired recovery contributes to further sleep disruption. This self-reinforcing cycle warrants assessment across multiple systems rather than attribution to a single cause.

GH also influences broader metabolic function. Clinical evidence links growth hormone activity to insulin sensitivity, lipid metabolism, and bone mineral density. Declining levels may produce effects extending beyond muscle and body composition. However, the direction and magnitude of these effects vary between individuals, and the evidence base for some metabolic outcomes remains at the level of observational studies rather than randomised controlled trials.

Natural Growth Hormone Decline (Somatopause)

Growth hormone output peaks during adolescence and begins a progressive decline from early adulthood. This gradual reduction, sometimes termed somatopause, is a normal physiological process. Published estimates suggest that GH secretion decreases by approximately 14 percent per decade after age 20, though this figure represents a population average and individual trajectories vary considerably.

This decline is not a disease. It is a physiological process that occurs across all adult populations. What varies significantly is the rate and severity of decline between individuals. Lifestyle factors, including sleep quality, body composition, exercise habits, and chronic stress exposure, all modulate GH output. Some men maintain robust secretion well into their 40s; others show measurable reductions by their mid-30s. The variation itself is informative, as it suggests that modifiable factors interact with the underlying age-related trajectory.

The clinical question is not whether GH declines; well-established evidence confirms it does in all adults. The relevant question is whether the degree of decline in a given individual is contributing to his symptom presentation, and whether further investigation through comprehensive pathology is warranted. Population reference ranges describe averages, not individuals. A man's trajectory relative to his own baseline may be more clinically informative than his position within a population range.

Symptoms of Low Growth Hormone in Adults

Low growth hormone in adults does not produce a single pathognomonic symptom. Instead, it tends to present as a cluster of changes that overlap substantially with other conditions and with normal ageing. This overlap is precisely what makes clinical assessment, rather than self-diagnosis, essential. The symptom picture alone is the starting point of the filtration cascade, not the endpoint.

Common Presentations

Symptoms that may be associated with reduced growth hormone output include increased adiposity, particularly visceral fat accumulation around the midsection; reduced lean muscle mass and diminished strength; decreased exercise capacity and prolonged recovery times; reduced bone mineral density; poor sleep quality, especially shallow or fragmented sleep architecture; fatigue and low energy that appear disproportionate to activity level; and shifts in lipid profiles and metabolic markers.

It is critical to recognise that each of these symptoms has multiple potential causes. Low GH output is one possibility among several, including thyroid dysfunction, low testosterone, chronic inflammation, sleep disorders, and metabolic syndrome. No single symptom points definitively to growth hormone as the cause. A systematic clinical assessment, incorporating symptom history alongside comprehensive pathology, helps determine whether GH is a contributing factor or whether the clinical picture points elsewhere.

Natural Decline vs Clinical Deficiency

There is an important clinical distinction between the natural age-related decline in GH output and clinical growth hormone deficiency (GHD). GHD is a diagnosable medical condition with specific diagnostic criteria, typically identified through dynamic stimulation testing and assessed by endocrinologists. The evidence base for GHD diagnosis and management is well established.

The natural decline most men experience is subtler and more gradual. GH-related markers may not meet the threshold criteria for clinical deficiency but may still sit at levels that contribute to symptoms. This intermediate zone, where levels are technically within population reference ranges but below an individual's historical baseline, is where a comprehensive hormonal assessment provides the most clinical value. Your treating practitioner can assess whether GH-related markers, particularly serum IGF-1, fall within expected ranges for your age and clinical context, and whether further investigation or specialist referral to an endocrinologist is appropriate.

How Growth Hormone Is Assessed Clinically

Growth hormone itself is difficult to measure directly because it is secreted in a pulsatile pattern, with levels fluctuating substantially throughout the day and peaking during sleep. A single random GH measurement is therefore unreliable as a clinical indicator. Instead, clinicians typically assess IGF-1 (insulin-like growth factor 1), which is produced by the liver in response to GH stimulation and provides a more stable, time-averaged marker of overall GH activity.

A thorough clinical assessment may include IGF-1 alongside a broader hormonal and metabolic panel: total and free testosterone, thyroid function (TSH, free T3, free T4), cortisol (stress hormone), inflammatory markers (signs of internal inflammation, including hsCRP and ESR), fasting glucose, HbA1c, and lipid profiles. This comprehensive approach reflects the principle that GH does not operate in isolation; its effects are interconnected with multiple hormonal and metabolic systems. A single marker assessed without context is a data point, not a clinical picture.

If your treating practitioner identifies findings consistent with clinical GH deficiency, they may recommend referral to an endocrinologist for formal dynamic stimulation testing and specialist evaluation. This is a clinical decision made on the basis of your individual presentation, not a standardised pathway applied to all patients. What constitutes an actionable finding depends on the convergence of symptoms, pathology, and clinical history.

Risks and Considerations

Growth hormone health is a complex clinical area where the therapeutic window, the balance between potential benefit and potential risk, requires careful practitioner assessment. Any clinical intervention in this space carries potential adverse effects and requires ongoing monitoring. Your treating practitioner will discuss specific risks and considerations relevant to your individual situation during your consultation. All prescribing pathways are TGA-compliant, and your practitioner will explain the regulatory framework relevant to your clinical situation.

Not all patients are suitable candidates for every clinical approach. Pre-existing conditions, current medications, cardiovascular risk factors, and individual metabolic profiles all influence what is and is not appropriate. In some cases, your practitioner may recommend lifestyle modifications, referral to an endocrinologist, or continuation of care with your GP rather than initiating a new management plan. The evidence supports individualised assessment over standardised protocols, and individual results vary. What remains under active investigation in the published literature is the long-term outcome profile for various approaches to GH-related health in ageing men, and your practitioner can discuss the current evidence base as it applies to your clinical picture.

Frequently Asked Questions

No. Growth hormone decline is a universal physiological process, with output decreasing from early adulthood. Growth hormone deficiency (GHD) is a diagnosable condition with specific clinical criteria, typically assessed through stimulation testing by an endocrinologist. Many men experience decline that does not meet the GHD threshold but may still contribute to increased visceral adiposity, reduced lean mass, or impaired recovery. An assessment including serum IGF-1 alongside broader hormonal and metabolic pathology helps determine where you sit on this spectrum.

Because growth hormone is secreted in pulses and fluctuates throughout the day, direct measurement is unreliable. Clinicians instead assess IGF-1 (insulin-like growth factor 1), a liver-derived marker providing a stable indication of overall GH activity. It is measured as part of a broader hormonal and metabolic panel including testosterone, thyroid function, cortisol, and fasting glucose. No single biomarker (measurable health indicator) provides a complete clinical picture. If findings suggest GH deficiency, your practitioner may recommend referral to an endocrinologist.

Published evidence indicates that several modifiable factors influence GH secretion. Deep slow-wave sleep is the primary trigger for GH release, so improvements in sleep quality may positively affect output. Resistance training and high-intensity exercise have been shown to stimulate acute GH secretion. Higher visceral adiposity is associated with reduced GH output, suggesting fat loss may support improved secretion. However, the magnitude of effect from lifestyle modification alone varies between individuals. A clinical assessment can identify modifiable factors alongside hormonal evaluation.

References

^[1] Fernandez-Garza LE, et al. "Growth hormone and aging: a clinical review." Frontiers in Aging, vol. 6, 2025, p. 1549453. [Link]
^[2] Greco EA, et al. "Osteoporosis and Sarcopenia Increase Frailty Syndrome in the Elderly." Frontiers in Endocrinology, vol. 10, 2019, p. 255. [Link]
^[3] Laurent MR, et al. "Age-related bone loss and sarcopenia in men." Maturitas, vol. 122, 2019, pp. 51-56. [Link]

Evidence-Based Growth Hormone Health Information

Regeniq is a registered Australian telehealth clinic facilitating practitioner-led medical consultations for men's hormonal and metabolic (how your body processes energy) health. Every consultation is conducted by an AHPRA-registered practitioner via live video, meeting the same clinical standard as a face-to-face appointment. Where clinically appropriate, licensed practitioners may prescribe through TGA-compliant pathways, and prescriptions may be dispensed through a registered compounding pharmacy staffed by licensed pharmacists. The clinical approach to growth hormone health begins with a comprehensive medical consultation that reviews symptom history, prior health records, and relevant pathology (blood testing) including IGF-1 (insulin-like growth factor 1) alongside broader hormonal and metabolic panels. This systematic, practitioner-led assessment builds a complete clinical picture before any recommendations are considered. All care is coordinated with your existing GP where appropriate. For men seeking evidence-based, registered telehealth consultations for hormonal health anywhere in Australia, our AHPRA-registered practitioners consult nationwide.

age-related muscle loss and performance

hormonal health assessment for men

losing strength despite consistent training?

body composition and growth hormone health

growth hormone and connective tissue health

Ready for a clinical assessment?

Want to learn more about evidence-based telehealth?

Book a Consultation

Understanding Growth Hormone Health in Men